These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 20353193

  • 1. Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity.
    Chen Z, Tian G, Wang Z, Jiang H, Shen J, Zhu W.
    J Chem Inf Model; 2010 Apr 26; 50(4):615-25. PubMed ID: 20353193
    [Abstract] [Full Text] [Related]

  • 2. Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies.
    John S, Thangapandian S, Sakkiah S, Lee KW.
    Eur J Med Chem; 2010 Sep 26; 45(9):4004-12. PubMed ID: 20580138
    [Abstract] [Full Text] [Related]

  • 3. Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors.
    Yang H, Shen Y, Chen J, Jiang Q, Leng Y, Shen J.
    Eur J Med Chem; 2009 Mar 26; 44(3):1167-71. PubMed ID: 18653260
    [Abstract] [Full Text] [Related]

  • 4. Novel method for generating structure-based pharmacophores using energetic analysis.
    Salam NK, Nuti R, Sherman W.
    J Chem Inf Model; 2009 Oct 26; 49(10):2356-68. PubMed ID: 19761201
    [Abstract] [Full Text] [Related]

  • 5. Fuzzy pharmacophore models from molecular alignments for correlation-vector-based virtual screening.
    Renner S, Schneider G.
    J Med Chem; 2004 Sep 09; 47(19):4653-64. PubMed ID: 15341481
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S, Thangapandian S, John S, Kwon YJ, Lee KW.
    Eur J Med Chem; 2010 Jun 09; 45(6):2132-40. PubMed ID: 20206418
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S, Alho-Richmond S, Wahala K.
    Mol Cell Endocrinol; 2009 Mar 25; 301(1-2):225-8. PubMed ID: 18822344
    [Abstract] [Full Text] [Related]

  • 16. Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads.
    Vadivelan S, Sinha BN, Rambabu G, Boppana K, Jagarlapudi SA.
    J Mol Graph Model; 2008 Feb 25; 26(6):935-46. PubMed ID: 17707666
    [Abstract] [Full Text] [Related]

  • 17. Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.
    Gangwal RP, Damre MV, Das NR, Dhoke GV, Bhadauriya A, Varikoti RA, Sharma SS, Sangamwar AT.
    J Mol Graph Model; 2015 Apr 25; 57():89-98. PubMed ID: 25687765
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.